Patents Represented by Attorney Boziecevic, Field & Francis, LLP
-
Patent number: 7670855Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.Type: GrantFiled: June 27, 2007Date of Patent: March 2, 2010Assignee: The Regents of the University of CaliforniaInventors: Richard S. Stephens, Diane Kawa
-
Patent number: 7153832Abstract: Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.Type: GrantFiled: April 1, 2004Date of Patent: December 26, 2006Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Roeland Nusse, Karl H. Willert
-
Patent number: 6939310Abstract: Methods and devices are provided for determining a suitable site for sampling physiological fluid. In the subject methods, a potentially suitable physiological sampling site is selected, the fluid flow of the site is characterized and the site is then determined to be suitable based on the whether the site has high or low flow. Suitability may also be determined based on the type of sample obtainable from the site, where the order of the above-described steps may be altered. The subject devices include at least one site flow characterization element for determining the flow characteristics of a potential physiological sampling site and/or at least one sample type characterization element for determining whether the vasculature is arterial, venous or neither, i.e., an interstitial fluid sampling site. The subject methods and devices are particularly suited for use in the detection of physiological sampling sites in the fingers, arms, legs, earlobes, heels, feet, nose and toes.Type: GrantFiled: October 10, 2001Date of Patent: September 6, 2005Assignee: LifeScan, Inc.Inventors: David Matzinger, Khalid R. Quraishi
-
Patent number: 6900049Abstract: The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.Type: GrantFiled: September 9, 1999Date of Patent: May 31, 2005Assignee: Cell Genesys, Inc.Inventors: De Chao Yu, Daniel R. Henderson
-
Patent number: 6844175Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications.Type: GrantFiled: November 8, 2001Date of Patent: January 18, 2005Assignees: The Regents of the University of the California, Syntex (U.S.A.) INCInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Patent number: 6676995Abstract: A method for laying down stripes of solution on substrate is described. The substrate preferably comprises a web of material set on a backing roller passed by a specially configured die. The die includes at least a mouth with lips extending beyond a face or body of the die. The die is adapted to avoid fluid leakage therefrom. Upper and lower portions of the die defining the mouth are preferably substantially flat and mirror images of each other. The lips are preferably placed in close proximity to the material on which the solution is to be deposited. Solution passing through the mouth of the die is directed to the webbing and deposited in a substantially constant thickness stripe or band. Often, the solution comprises a reagent-type solution. The solution coating is typically dried onto the substrate. Dried product may then be used in reagent test strip production.Type: GrantFiled: June 28, 2002Date of Patent: January 13, 2004Assignee: LifeScan, Inc.Inventors: Kenneth W. Dick, Gary Otake, Aaron Jessen
-
Patent number: 6570040Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).Type: GrantFiled: March 16, 2001Date of Patent: May 27, 2003Assignee: The Regents of the University of CaliforniaInventors: Eliana Saxon, Carolyn Bertozzi
-
Patent number: 6518043Abstract: A novel protein having the activity to suppress proliferation of lympho-hematopoietic cells derived from BNS2.4 cells, its gene, a method for preparing them and their uses are provided. The novel protein has been identified from a stromal cell line BMS2.4 by expression cloning targeting mouse myelomonocytic leukemia cell line WEHI3. This protein and its gene are useful for treating lympho-hematopoietic disorders.Type: GrantFiled: March 13, 2000Date of Patent: February 11, 2003Assignees: Oklahoma Medical Research Foundation, Center for Advanced Science and Technology Incubation, Ltd.Inventors: Kenji Oritani, Yoshiaki Tomiyama, Yuji Matsuzawa, Paul W. Kincade
-
Patent number: 6358751Abstract: Allograft rejection is initiated by an immune response to donor major histocompatibility complex proteins. After allogeneic heart transplantation, de novo CD4+ T cell and B cell autoimmune responses to contractile proteins of cardiac muscle, e.g. cardiac myosin (CM), are elicited. The transplantation induced autoimmune response to cardiac myosin plays an significant role in cardiac transplant rejection. Methods are provided for diagnosis and therapy of graft rejection.Type: GrantFiled: May 12, 1999Date of Patent: March 19, 2002Assignee: The Regents of the University of CaliforniaInventors: Gilles Benichou, Eugenia Fedoseyeva
-
Patent number: D505017Type: GrantFiled: August 11, 2003Date of Patent: May 17, 2005Assignee: Picture the Cure, Inc.Inventor: Brandon Paul Rodriguez